As such, the effect of monoclonal antibodies against these kinases often depends on the KRAS or BRAF status of the tumor, which is another reason why understanding the molecular pathogenesis of the cancer is crucial in deciding the appropriate treatment [5]. This evidence concerns the gene KRAS and cancer.